Niels van Nieuwenhuijzen, MD, University Medical Center Utrecht, Utrecht, Netherlands, shares the results of a study investigating response to venetoclax in a hydrogel model of AL amyloidosis plasma cells, describing the features and advantages of this model. Overall, the study did not demonstrate a difference in response to venetoclax between t(11;14)-positive and negative amyloidosis plasma cells. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.